Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.45 |
| ▸ | LIG1 | P18858 | 1/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29430083 | 0.98 | KDM1A (0.47) | KDM1ARCOR1LIG1SLC9A1PTGS2 | |
| Water SCHEMBL2458176 | 0.98 | KDM1A (0.44) | KDM1ARCOR1LIG1SLC9A1PTGS2 | |
| SCHEMBL4134830 | 0.91 | KDM1A (0.41) | KDM1ARCOR1LIG1SLC9A1PTGS2 | |
| SCHEMBL29453536 | 0.86 | KDM1A (0.41) | KDM1ARCOR1LIG1SLC9A1PTGS2 | |
| SCHEMBL5683641 | 0.86 | OPRK1 (0.43) | KDM1ARCOR1LIG1SLC9A1KCNH2 | |
| Malic Acid SCHEMBL29430071 | 0.83 | SMN1; SMN2 (0.39) | KDM1ARCOR1LIG1PTGS2HSD11B1 | |
| SCHEMBL28519822 | 0.81 | ALDH1A1 (0.40) | MAOBALDH1A1MAOA | |
| SCHEMBL28521164 | 0.81 | KDM1A (0.45) | KDM1ARCOR1LIG1SLC9A1PTGS2 | |
| SCHEMBL28511550 | 0.81 | KDM1A (0.45) | KDM1ARCOR1LIG1MAOBMAOA | |
| SCHEMBL307974 | 0.81 | KDM1A (0.48) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | claimed |
| CN-107793363-A | A kind of substituted aromatic amines base heteroaromatic class compound and its application as antineoplastic | 上海医药工业研究院 | 2018-03-13 | — | — | CN | claimed |
| WO-2009077874-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R & D MANAGEMENT CO., LTD. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12227481-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | EXELIXIS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-114040912-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-10-25 | — | — | CN | disclosed |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-107325048-A | Use the method for c Met conditioning agents | 埃克塞里艾克西斯公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-104045642-B | Containing pyrimidine or the fused ring compound of pyridine and the application as antitumor drug thereof | 上海医药工业研究院 | 2016-08-24 | — | — | CN | disclosed |
| EP-2454238-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | Exelixis, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2339918-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GlaxoSmithKline LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2011009095-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUIN0LIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009077874-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R & D MANAGEMENT CO., LTD. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM1A 4241/4885RCOR1 3124/4885LIG1 2936/4885 |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | KDM1A 2938/4885RCOR1 2341/4885LIG1 3396/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | KDM1A 2806/4885RCOR1 2607/4885LIG1 3663/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | KDM1A 742/4885RCOR1 511/4885LIG1 3056/4885 |
| US-12227481-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | RCC1, RCC2, CALU | KDM1A 1353/4885RCOR1 1592/4885LIG1 4787/4885 |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | KDM1A 719/4885RCOR1 450/4885LIG1 3025/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | KDM1A 91/4885RCOR1 865/4885LIG1 608/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | KDM1A 2938/4885RCOR1 2341/4885LIG1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.